Metsera (NASDAQ:MTSR) Shares Down 12.6% – Here’s Why

Metsera, Inc. (NASDAQ:MTSR) shares dropped 12.6% on Wednesday . The company traded as low as $12.40 and last traded at $12.42. Approximately 285,175 shares traded hands during trading, a decline of 62% from the average daily volume of 747,144 shares. The stock had previously closed at $14.21.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Bank of America started coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $38.00 price target for the company. Guggenheim began coverage on Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $56.00 target price for the company. Cantor Fitzgerald began coverage on Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating on the stock. Finally, Evercore ISI started coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued an “outperform” rating on the stock.

Metsera Price Performance

The business has a 50 day moving average of $26.79.

Metsera (NASDAQ:MTSR) last announced its quarterly earnings results on Wednesday, March 26th. The company reported ($3.52) earnings per share (EPS) for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.